Plain-English translation of NCT04347434 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing atorvastatin, a cholesterol-lowering medication, given to people within the first few days after a heart attack. Researchers want to understand how well this medication helps the heart recover over time and whether adding a second medication (ezetimibe) helps patients reach their cholesterol goals better. The study will track heart function, heart muscle behavior, blood vessel stiffness, and overall quality of life.
After a heart attack, lowering cholesterol quickly is important to prevent future heart problems, but doctors want to know the best way to do this. This trial will help show whether starting the medication immediately and adjusting doses based on individual needs leads to better heart recovery and overall outcomes.
You likely qualify if…
You likely don't qualify if…
You would take atorvastatin 80 mg daily starting within days of your heart attack as part of standard care. About 5–6 weeks later, your cholesterol levels would be checked, and if needed, a second medication (ezetimibe) would be added. Throughout the study, you would have heart ultrasounds, heart monitoring tests, blood tests, and quality-of-life assessments to see how well your heart is recovering and how the medication affects you over time.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Russia